Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Cash & Current Investments (2016 - 2025)

ImmunityBio (IBRX) has disclosed Cash & Current Investments for 13 consecutive years, with $242.8 million as the latest value for Q4 2025.

  • Quarterly Cash & Current Investments rose 62.09% to $242.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $242.8 million through Dec 2025, up 62.09% year-over-year, with the annual reading at $242.8 million for FY2025, 62.09% up from the prior year.
  • Cash & Current Investments for Q4 2025 was $242.8 million at ImmunityBio, down from $257.8 million in the prior quarter.
  • The five-year high for Cash & Current Investments was $317.1 million in Q4 2021, with the low at $46.0 million in Q2 2023.
  • Average Cash & Current Investments over 5 years is $152.8 million, with a median of $140.1 million recorded in 2024.
  • The sharpest move saw Cash & Current Investments tumbled 66.2% in 2022, then surged 374.34% in 2024.
  • Over 5 years, Cash & Current Investments stood at $317.1 million in 2021, then crashed by 66.2% to $107.2 million in 2022, then soared by 148.6% to $266.5 million in 2023, then crashed by 43.78% to $149.8 million in 2024, then soared by 62.09% to $242.8 million in 2025.
  • According to Business Quant data, Cash & Current Investments over the past three periods came in at $242.8 million, $257.8 million, and $153.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.